Cargando…
Human bronchial carcinoid tumor initiating cells are targeted by the combination of acetazolamide and sulforaphane
BACKGROUND: Bronchial carcinoids are neuroendocrine tumors that present as typical (TC) and atypical (AC) variants, the latter being more aggressive, invasive and metastatic. Studies of tumor initiating cell (TIC) biology in bronchial carcinoids has been hindered by the lack of appropriate in-vitro...
Autores principales: | Bayat Mokhtari, Reza, Baluch, Narges, Morgatskaya, Evgeniya, Kumar, Sushil, Sparaneo, Angelo, Muscarella, Lucia Anna, Zhao, Sheyun, Cheng, Hai-Ling, Das, Bikul, Yeger, Herman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716820/ https://www.ncbi.nlm.nih.gov/pubmed/31470802 http://dx.doi.org/10.1186/s12885-019-6018-1 |
Ejemplares similares
-
Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis
por: Mokhtari, Reza Bayat, et al.
Publicado: (2021) -
Correction: Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis
por: Mokhtari, Reza Bayat, et al.
Publicado: (2022) -
Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines
por: Mokhtari, Reza Bayat, et al.
Publicado: (2013) -
Combination therapy in combating cancer
por: Mokhtari, Reza Bayat, et al.
Publicado: (2017) -
Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma
por: Bayat Mokhtari, Reza, et al.
Publicado: (2017)